(Q43289851)

English

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

scientific article published on 19 August 2009

Statements

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group (English)
Kazuhiko Nakagami
Mitsuhiro Mizutani
Fumine Tsukamoto
Noriyuki Masuda
Shinzaburo Noguchi

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit